Topic: monoclonal antibody
The round will push Adagene's lead immunotherapies through the clinic as well as support further development of its drug discovery technology.
AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.
Immunitas Therapeutics is launching with $39 million in series A financing to propel at least one monoclonal antibody into the clinic.
Third Rock startup Goldfinch plans to file an IND for its treatment for rare and metabolic kidney diseases in the second half of next year.
The deal sees Gilead Sciences task AbCellera with using technologies to find rare antibodies with certain characteristics.
Another day, another biopharma veteran hits the exit and walks straight into the arms of Vivek Ramaswamy.
BioNTech has bought up MabVax Therapeutics’ cancer drug assets alongside much of its infrastructure and labs.
AgomAb Therapeutics is coming out of stealth with €21 million to develop agonistic monoclonal antibodies that could potentially treat a range of diseases.
University of Tennessee scientists have designed a CD19-targeting CAR-T for lupus and have shown encouraging results in a mouse study.
Purdue Pharma’s new R&D subsidiary, Imbrium Therapeutics, tapped TetraGenetics and its antibody discovery platform for non-opioid-based painkillers.